RADX Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Radiopharm Theranostics

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

7 days ago - By: Benzinga - Mentions: ALKS ENGN IMMP MLSS ...

12 Health Care Stocks Moving In Thursday's After-Market Session

16 days ago - By: Virtual Investor Conferences - Mentions: LSE - HCM VIOT ...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

21 days ago - By: Virtual Investor Conferences - Mentions: HCM LSE - YRD ...

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

22 days ago - By: Virtual Investor Conferences - Mentions: HCM LSE - YRD ...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

24 days ago - By: Benzinga - Mentions: AZTR SNTI ADAP CODX ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Radiopharm Theranostics

Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

2 months ago - By: Radiopharm Theranostics

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial

4 months ago - By: Radiopharm Theranostics

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

4 months ago - By: Radiopharm Theranostics

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

5 months ago - By: Radiopharm Theranostics

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

6 months ago - By: Radiopharm Theranostics

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

6 months ago - By: Radiopharm Theranostics

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

6 months ago - By: Radiopharm Theranostics

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

7 months ago - By: Radiopharm Theranostics

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

8 months ago - By: Radiopharm Theranostics

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

9 months ago - By: Radiopharm Theranostics

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

a year ago - By: Radiopharm Theranostics

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

a year ago - By: Radiopharm Theranostics

RADIOPHARM THERANOSTICS LTD (RADX) Stock News

RADX Latest News, Press Relases and Analysis

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

12 Health Care Stocks Moving In Thursday's After-Market Session

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

12 Health Care Stocks Moving In Monday's After-Market Session

Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial